Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Aphios Corporation
Aphios Corporation Executes Collaborative R&D Agreement with VivaCell Biotechnology Espana to Develop Combination Therapy for HIV Latency
April 8th, 2009
Aphios Corporation announced entering into a Collaborative Research and Development Agreement with VivaCell Biotechnology Espana S.L., Cordoba, Spain to develop a combination therapy for the treatment of HIV latency. Currently, over 22 million people have died from AIDS and there are over 42 million people living with HIV/AIDS worldwide. There is no vaccine against HIV, and AIDS, if untreated, will lead to the death of over 95% of infected individuals 10 years post-infection. HIV infects several cell types during the course of infection and progression to acquired immune deficiency syndrome (AIDS). The persistence of latent HIV-infected cellular reservoirs represents...
Source: Vaccine Weekly (2009-04-08)
|
